240 related articles for article (PubMed ID: 16763574)
1. Reverse mergers attract top-tier biotechs in sluggish IPO market.
Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):598-9. PubMed ID: 16763574
[No Abstract] [Full Text] [Related]
2. Shareholders flex their muscles.
Thiel K
Nat Biotechnol; 2008 Jan; 26(1):19-21. PubMed ID: 18183007
[No Abstract] [Full Text] [Related]
3. Evolving symbiosis--venture capital and biotechnology.
Bradford TC
Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
[No Abstract] [Full Text] [Related]
4. Does biotech M&A benefit investors?
Jacobs T
Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
[No Abstract] [Full Text] [Related]
5. Earlier stage biotechs attract partners.
Ratner M
Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
[No Abstract] [Full Text] [Related]
6. Biotechs await single European financial market.
Louët S
Nat Biotechnol; 2003 Dec; 21(12):1417. PubMed ID: 14647312
[No Abstract] [Full Text] [Related]
7. Filters for preparing to meet a venture capitalist.
Christoffersen R
Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
[No Abstract] [Full Text] [Related]
8. Convincing a venture capitalist to invest in your idea.
Dooley JF; Dooley JF
Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
[No Abstract] [Full Text] [Related]
9. Antiinfective biotechs face partnering gap.
Sheridan C
Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
[No Abstract] [Full Text] [Related]
10. GSK moves on Sirtris.
Sipp D
Nat Biotechnol; 2008 Jun; 26(6):595. PubMed ID: 18536662
[No Abstract] [Full Text] [Related]
11. IPO plans sour on both sides of the pond.
Mitchell P
Nat Biotechnol; 2004 Aug; 22(8):929-30. PubMed ID: 15286629
[No Abstract] [Full Text] [Related]
12. Millennium ends Takeda's US shopping spree.
Sipp D
Nat Biotechnol; 2008 Jun; 26(6):593-5. PubMed ID: 18536661
[No Abstract] [Full Text] [Related]
13. Partnerships in African crop biotech.
Ayele S; Chataway J; Wield D
Nat Biotechnol; 2006 Jun; 24(6):619-21. PubMed ID: 16763585
[TBL] [Abstract][Full Text] [Related]
14. The term sheet tango.
Willey T; Parsigian D
Nat Biotechnol; 2003 Jul; 21 Suppl():BE29-30. PubMed ID: 12874974
[No Abstract] [Full Text] [Related]
15. Exiting this year and into the next.
Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
[No Abstract] [Full Text] [Related]
16. Shift toward early-stage deals favors biotechs.
Lawrence S
Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
[No Abstract] [Full Text] [Related]
17. Cash-strapped biotechs find financing alternative.
Mitchell P
Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
[No Abstract] [Full Text] [Related]
18. Can Europe accelerate out of trouble?
Nat Biotechnol; 2006 Sep; 24(9):1040. PubMed ID: 16964194
[No Abstract] [Full Text] [Related]
19. European markets target foreign biotechs.
Louët S
Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
[No Abstract] [Full Text] [Related]
20. Selling out.
Martin JF
Nat Biotechnol; 2010 Apr; 28(4):315-7. PubMed ID: 20383912
[No Abstract] [Full Text] [Related]
[Next] [New Search]
